share_log

啓明醫療-B：(1) 復牌進展第四季度更新；及(2) 繼續暫停買賣

VENUS MEDTECH-B: (1) THE FOURTH QUARTERLY UPDATE ON RESUMPTION PROGRESS; AND(2) CONTINUED SUSPENSION OF TRADING

HKEX ·  Nov 22, 2024 05:33

Summary by Moomoo AI

杭州啓明醫療器械有限公司於2024年11月22日發佈公告，更新了復牌進展和內部控制措施。該公司自2023年11月23日起暫停交易，並將繼續暫停交易，直到滿足證券交易所設定的復牌指導方針。公司已經實施了多項內部控制改進措施，包括實施 「籌款管理體系」 和 「內部審計管理體系」，以加強財務、法律和內部審計部門的職能分工。 該公司已經完成了對未經授權交易的法證調查，並確認相關員工已不再擔任管理職務。公司還改善了海外子公司的審批制度，並任命朱冰先生爲首席財務官。董事會提議召開特別股東大會，考慮任命顧軍華先生爲獨立非執行董事，以遵守上市規則。 此外，該公司已經完成了對所得款項用途的審查，並將根據補充審查的結果發佈進一步的公告。該公司強調，未經授權的交易不會對日常業務運營產生重大不利影響，並將繼續回應證券交易所的意見和詢問。
杭州啓明醫療器械有限公司於2024年11月22日發佈公告，更新了復牌進展和內部控制措施。該公司自2023年11月23日起暫停交易，並將繼續暫停交易，直到滿足證券交易所設定的復牌指導方針。公司已經實施了多項內部控制改進措施，包括實施 「籌款管理體系」 和 「內部審計管理體系」，以加強財務、法律和內部審計部門的職能分工。 該公司已經完成了對未經授權交易的法證調查，並確認相關員工已不再擔任管理職務。公司還改善了海外子公司的審批制度，並任命朱冰先生爲首席財務官。董事會提議召開特別股東大會，考慮任命顧軍華先生爲獨立非執行董事，以遵守上市規則。 此外，該公司已經完成了對所得款項用途的審查，並將根據補充審查的結果發佈進一步的公告。該公司強調，未經授權的交易不會對日常業務運營產生重大不利影響，並將繼續回應證券交易所的意見和詢問。
Hangzhou Qiming Medical Instruments Co., Ltd. issued an announcement on November 22, 2024, updating the progress of resumption and internal control measures. The company has suspended trading since November 23, 2023, and will continue to suspend until the resumption guidelines set by the stock exchange are met. The company has implemented several internal control improvements, including the implementation of the "Fundraising Management System" and "Internal Audit Management System," to strengthen the functional division of the finance, legal, and internal audit departments. The company has completed a forensic investigation of unauthorized trades and confirmed that the relevant employees are no longer in management positions. The company has also improved the approval system for overseas subsidiaries and appointed Mr. Zhu Bing as Chief Financial Officer. The...Show More
Hangzhou Qiming Medical Instruments Co., Ltd. issued an announcement on November 22, 2024, updating the progress of resumption and internal control measures. The company has suspended trading since November 23, 2023, and will continue to suspend until the resumption guidelines set by the stock exchange are met. The company has implemented several internal control improvements, including the implementation of the "Fundraising Management System" and "Internal Audit Management System," to strengthen the functional division of the finance, legal, and internal audit departments. The company has completed a forensic investigation of unauthorized trades and confirmed that the relevant employees are no longer in management positions. The company has also improved the approval system for overseas subsidiaries and appointed Mr. Zhu Bing as Chief Financial Officer. The board of directors has proposed to hold an extraordinary general meeting of shareholders to consider appointing Mr. Gu Junhua as an independent non-executive director to comply with the listing rules. In addition, the company has completed a review of the use of proceeds and will issue further announcements based on the results of the supplementary review. The company emphasizes that unauthorized trading has no significant adverse impact on daily business operations and will continue to respond to the opinions and inquiries of the stock exchange.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    MEDBOT-B
    02252
    -- 14.260
    GBG HOLDINGS
    08372
    -- 0.098
    CRYOFOCUS-B
    06922
    -- 7.370
    MICROPORT NEURO
    02172
    -- 9.280
    MICROTECH MED-B
    02235
    -- 5.220
    Log In for the Full List
    Discussing
    Trump 2.0 Era: What's the next opportunity in the markets?
    ▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks Show More
    Ask a strategist - Trump's first day
    China Concept Stocks
    Tracking the US-listed Chinese companies.